<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">CTQQnRY9tjxw8KzmTvLhsTR</article-id>
      <article-id pub-id-type="other">00018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001400018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500418</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000120</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avalia&#231;&#227;o da hipertens&#227;o arterial resistente pela monitoriza&#231;&#227;o residencial da press&#227;o arterial</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Marui</surname>
            <given-names>Fabiane Rosa Rezende H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bombig</surname>
            <given-names>Maria Teresa Nogueira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Francisco</surname>
            <given-names>Yon&#225; Afonso</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thalenberg</surname>
            <given-names>Jos&#233; Marcos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fonseca</surname>
            <given-names>Francisco Antonio Helfenstein</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Dilma de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Francisco de Assis</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Izar</surname>
            <given-names>Maria Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Antonio Carlos de Camargo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>P&#243;voa</surname>
            <given-names>Rui</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Escola Paulista de Medicina </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>4</issue>
      <fpage>536</fpage>
      <lpage>540</lpage>
      <history>
        <date date-type="rev-recd">
          <day>03</day>
          <month>02</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>18</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>03</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA) &#233; considerada o padr&#227;o-ouro para a confirma&#231;&#227;o diagn&#243;stica da hipertens&#227;o arterial resistente (HAR). No entanto, a monitoriza&#231;&#227;o residencial da press&#227;o arterial (MRPA) tem sido considerada uma op&#231;&#227;o, pelo seu custo menor e maior conforto. OBJETIVO: Comparar os valores obtidos pela MRPA com os obtidos pela MAPA na identifica&#231;&#227;o de pacientes hipertensos resistentes. M&#201;TODOS: Foram selecionados consecutivamente 51 pacientes hipertensos resistentes, adultos de ambos os sexos, em tratamento ambulatorial de refer&#234;ncia, de jan/2007 a set/2009. A medida da press&#227;o arterial (PA) casual de consult&#243;rio, MAPA de 24 horas e MRPA foram realizadas conforme as diretrizes vigentes, com intervalo m&#225;ximo de duas semanas entre os m&#233;todos. RESULTADOS: Ao comparar a MAPA (m&#233;dia de vig&#237;lia) e MRPA, foi obtida boa correla&#231;&#227;o entre ambas, tanto para a press&#227;o arterial sist&#243;lica (PAS) quanto para a diast&#243;lica (PAD): PAS r = 0,70, IC = 0,51-0,82; PAD r = 0,69, IC = 0,52-0,81. A HAR foi confirmada pela MAPA em 33 pacientes e pela MRPA em 37 desses, n&#227;o havendo diferen&#231;a significante entre os dois m&#233;todos. CONCLUS&#195;O: De acordo com os resultados obtidos, conclui-se que a MRPA &#233; um exame que pode ser utilizado como alternativa &#224; MAPA para a confirma&#231;&#227;o diagn&#243;stica da HAR.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Hipertens&#227;o</kwd>
        <kwd>monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial</kwd>
        <kwd>press&#227;o arterial</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>08</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> MAPEAMENTO AMBULATORIAL DA PA (MAPA) </p>
    <p>
      <bold>Avalia&#231;&#227;o da hipertens&#227;o arterial resistente pela monitoriza&#231;&#227;o residencial da press&#227;o arterial</bold>
    </p>
    <p>
      <bold>Fabiane Rosa Rezende H. Marui; Maria Teresa Nogueira Bombig; Yon&#225; Afonso Francisco; Jos&#233; Marcos Thalenberg; Francisco Antonio Helfenstein Fonseca; Dilma de Souza; Francisco de Assis Costa; Maria Cristina Izar; Antonio Carlos de Camargo Carvalho; Rui P&#243;voa</bold>
    </p>
    <p> Universidade Federal de S&#227;o Paulo - Escola Paulista de Medicina, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial (MAPA) &#233; considerada o padr&#227;o-ouro para a confirma&#231;&#227;o diagn&#243;stica da hipertens&#227;o arterial resistente (HAR). No entanto, a monitoriza&#231;&#227;o residencial da press&#227;o arterial (MRPA) tem sido considerada uma op&#231;&#227;o, pelo seu custo menor e maior conforto. </p>
    <p><bold>OBJETIVO:</bold> Comparar os valores obtidos pela MRPA com os obtidos pela MAPA na identifica&#231;&#227;o de pacientes hipertensos resistentes. </p>
    <p><bold>M&#201;TODOS:</bold> Foram selecionados consecutivamente 51 pacientes hipertensos resistentes, adultos de ambos os sexos, em tratamento ambulatorial de refer&#234;ncia, de jan/2007 a set/2009. A medida da press&#227;o arterial (PA) casual de consult&#243;rio, MAPA de 24 horas e MRPA foram realizadas conforme as diretrizes vigentes, com intervalo m&#225;ximo de duas semanas entre os m&#233;todos. </p>
    <p><bold>RESULTADOS:</bold> Ao comparar a MAPA (m&#233;dia de vig&#237;lia) e MRPA, foi obtida boa correla&#231;&#227;o entre ambas, tanto para a press&#227;o arterial sist&#243;lica (PAS) quanto para a diast&#243;lica (PAD): PAS r = 0,70, IC = 0,51-0,82; PAD r = 0,69, IC = 0,52-0,81. A HAR foi confirmada pela MAPA em 33 pacientes e pela MRPA em 37 desses, n&#227;o havendo diferen&#231;a significante entre os dois m&#233;todos. </p>
    <p><bold>CONCLUS&#195;O:</bold> De acordo com os resultados obtidos, conclui-se que a MRPA &#233; um exame que pode ser utilizado como alternativa &#224; MAPA para a confirma&#231;&#227;o diagn&#243;stica da HAR. </p>
    <p><bold>Palavras-chave: </bold>Hipertens&#227;o, monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial, press&#227;o arterial/efeitos de drogas.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A hipertens&#227;o arterial (HA) tem alta preval&#234;ncia no Brasil e apresenta custos m&#233;dicos e socioecon&#244;micos muito elevados, dadas as complica&#231;&#245;es dela decorrentes. A redu&#231;&#227;o da PA diminui os riscos do aparecimento de tais complica&#231;&#245;es, por&#233;m o seu controle s&#243; &#233; conseguido em uma minoria dos pacientes hipertensos<sup>1</sup>. No Brasil, estima-se que apenas 10,0% da popula&#231;&#227;o hipertensa esteja com PA controlada, seja por falta de diagn&#243;stico, de tratamento, seja por dificuldades no controle da doen&#231;a<sup>2</sup>. A resist&#234;ncia ao tratamento da HA pode estar presente em 20,0% a 40,0% dos hipertensos<sup>3</sup>.</p>
    <p>A HAR &#233; definida pela constata&#231;&#227;o de valores da PA casual em consult&#243;rio persistentemente acima das metas de controle em paciente usando pelo menos tr&#234;s classes de anti-hipertensivos, incluindo um diur&#233;tico sempre que poss&#237;vel, em dosagens otimizadas<sup>4</sup>.</p>
    <p>V&#225;rios fatores influenciam a identifica&#231;&#227;o da HAR, tais como: t&#233;cnica incorreta de mensura&#231;&#227;o da PA, baixa ades&#227;o ao tratamento e eleva&#231;&#227;o da PA apenas em ambiente m&#233;dico (efeito do avental branco)<sup>4</sup>. Esses fatores podem levar &#224; "pseudorresist&#234;ncia", que &#233; uma aparente falta de controle da PA quando verificada em consult&#243;rio. Se a t&#233;cnica e a ades&#227;o s&#227;o satisfat&#243;rias, mas o efeito do avental branco altera o diagn&#243;stico, configura-se a chamada HAR do avental branco<sup>5</sup>. A &#250;nica forma de identificar corretamente esta condi&#231;&#227;o &#233; por meio das monitoriza&#231;&#245;es da PA<sup>6</sup>.</p>
    <p>A MAPA, considerada o padr&#227;o-ouro para a confirma&#231;&#227;o diagn&#243;stica da HAR, ainda &#233; um procedimento caro e n&#227;o aplic&#225;vel &#224; maioria da popula&#231;&#227;o. No entanto, a MRPA tem sido amplamente estudada, pois se trata de um exame de f&#225;cil aplica&#231;&#227;o e boa aceitabilidade pelos pacientes<sup>7</sup>. Assim, o objetivo desta pesquisa foi comparar os valores obtidos pela MRPA com aqueles obtidos pela MAPA, aferindo-se a validade do m&#233;todo na identifica&#231;&#227;o de pacientes hipertensos resistentes.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Pacientes</bold>
    </p>
    <p>Foram selecionados consecutivamente 51 pacientes hipertensos, em uso de pelo menos tr&#234;s classes de anti-hipertensivos em dosagens otimizadas, sendo uma delas um diur&#233;tico, em tratamento no Setor de Cardiopatia Hipertensiva da Universidade Federal de S&#227;o Paulo - UNIFESP, no per&#237;odo de jan/2007 a set/2009. </p>
    <p>O Comit&#234; de &#201;tica em Pesquisa aprovou o protocolo de pesquisa e todos os pacientes assinaram o termo de consentimento livre e esclarecido, de acordo com os princ&#237;pios da Declara&#231;&#227;o de Helsinki.</p>
    <p>No estudo, foram inclu&#237;dos pacientes que apresentaram PAS <underline>&gt;</underline> 140 mmHg e/ou PAD <underline>&gt;</underline> 90 mmHg no consult&#243;rio (ou <underline>&gt;</underline> 130 x 80 mmHg em diab&#233;ticos e em pacientes com les&#227;o renal), considerando-se a m&#233;dia de duas das tr&#234;s medidas realizadas em ambos os membros superiores (levadas em conta as medidas do membro com valores mais elevados). A hipertens&#227;o secund&#225;ria foi sistematicamente investigada nos pacientes, utilizando-se rastreamento padronizado conforme protocolo usado no Setor, baseado na primeira diretriz da <italic>American Heart Association</italic> sobre HAR<sup>6</sup>.</p>
    <p>Uma avalia&#231;&#227;o cl&#237;nica completa dos pacientes foi realizada, incluindo os medicamentos em uso e fatores relacionados ao estilo de vida, como consumo de &#225;lcool e tabagismo, assim como pr&#225;tica habitual de atividade f&#237;sica. Foram verificadas as medidas antropom&#233;tricas, que constaram de altura, peso, circunfer&#234;ncias abdominal e do quadril. Para a determina&#231;&#227;o de diabete ou les&#227;o renal, foi utilizada avalia&#231;&#227;o laboratorial rotineira.</p>
    <p>Para a medida da PA casual de consult&#243;rio, foi utilizado o m&#233;todo auscultat&#243;rio com esfigmoman&#244;metro de coluna de merc&#250;rio. Foram realizadas tr&#234;s medidas em cada bra&#231;o, com um intervalo de um minuto entre as medidas, estando o paciente sentado e em repouso por 5 minutos. Considerou-se a m&#233;dia das duas &#250;ltimas medidas no membro cujos valores foram os mais elevados<sup>2</sup>.</p>
    <p>Em sequ&#234;ncia, a realiza&#231;&#227;o da MAPA e da MRPA era agendada. Os monitores para MAPA (<italic>Spacelabs 90207<sup>&#174;</sup></italic>) foram programados para aferir a PA, a cada 15 minutos (vig&#237;lia) e a cada 30 minutos (sono) durante 24 horas, com manguito apropriado alocado no bra&#231;o n&#227;o dominante. Os hor&#225;rios de dormir e despertar foram estabelecidos individualmente e checados de acordo com os registros do di&#225;rio. </p>
    <p>Quanto &#224; MRPA, foram realizadas tr&#234;s medidas da PA pela manh&#227; e &#224; noite, durante 5 dias consecutivos, sendo o primeiro dia reservado para orienta&#231;&#245;es, de acordo com a IV Diretriz para Uso da Monitoriza&#231;&#227;o Ambulatorial da Press&#227;o Arterial e II Diretriz para Uso da Monitoriza&#231;&#227;o Residencial da Press&#227;o Arterial da Sociedade Brasileira de Cardiologia<sup>8</sup>. Al&#233;m de orienta&#231;&#227;o verbal, o participante recebeu uma cartilha com a descri&#231;&#227;o dos m&#233;todos. Foi utilizado aparelho semiautom&#225;tico validado (<italic>Microlife BP 3AC1-1<sup>&#174;</sup></italic>). O intervalo entre a medida casual de consult&#243;rio, a instala&#231;&#227;o da MAPA e MRPA n&#227;o foi superior a duas semanas.</p>
    <p>
      <bold>Crit&#233;rios diagn&#243;sticos</bold>
    </p>
    <p>Para a medida de PA casual, consideraram-se como HAR valores para a PAS <underline>&gt;</underline> 140 mmHg e/ou para a PAD <underline>&gt;</underline> 90 mmHg (ou <underline>&gt;</underline> 130 mmHg e/ou 80 mmHg em diab&#233;ticos e em pacientes com les&#227;o renal). Para a MAPA, foram consideradas as m&#233;dias de vig&#237;lia <underline>&gt;</underline> 135 mmHg (PAS) ou 85 mmHg (PAD), observando-se as mesmas cifras para a MRPA em pacientes devidamente medicados.</p>
    <p>O diagn&#243;stico de diabete melito foi estabelecido para pacientes com glicemia de jejum <underline>&gt;</underline> 126 mg/dl ou em tratamento para tal. Para les&#227;o renal, foi considerada taxa de filtra&#231;&#227;o glomerular &lt; 60 ml/min/1,73 m<sup>2</sup>, estimada pela f&#243;rmula de Cockcroft-Gault.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Os resultados foram expressos em m&#233;dias e desvio-padr&#227;o. Foram utilizados os testes do qui-quadrado e a correla&#231;&#227;o linear de Pearson para a an&#225;lise dos resultados. Para a verifica&#231;&#227;o de signific&#226;ncia estat&#237;stica foram considerados intervalos de confian&#231;a de 95,0% e p &lt; 0,05.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Participaram do estudo 28 homens (55,0%) e 23 mulheres (45,0%), com idade entre 34 e 74 anos (m&#233;dia de 56,4 &#177; 10 anos). A <xref ref-type="table" rid="tab01">Tabela 1</xref> resume as caracter&#237;sticas da popula&#231;&#227;o do estudo quanto a dados antropom&#233;tricos e a presen&#231;a de fatores de risco cardiovascular. Destaca-se a presen&#231;a de sobrepeso e obesidade (84,0% da amostra), sendo que 6 pacientes tinham &#237;ndice de massa corp&#243;rea (IMC) <underline>&gt;</underline> 40 (obesidade m&#243;rbida). Apenas 5 homens e uma mulher apresentaram rela&#231;&#227;o cintura-quadril adequado (<underline>&lt;</underline> 0,90 e 0,85, respectivamente). Quanto &#224;queles que autorreferiam a presen&#231;a de ronco durante o sono (61,0% da amostra), todos tinham IMC <underline>&gt;</underline> 25.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt01.jpg"/></table-wrap>
    <p>As medica&#231;&#245;es anti-hipertensivas mais prescritas foram: tiaz&#237;dicos (hidroclorotiazida, com 34 prescri&#231;&#245;es e clortalidona, com 17 prescri&#231;&#245;es), captopril (24 prescri&#231;&#245;es), amlodipina (36 prescri&#231;&#245;es), propranolol (22 prescri&#231;&#245;es). Al&#233;m desses, 22 pacientes faziam uso de antiagregantes plaquet&#225;rios.</p>
    <p>A <xref ref-type="table" rid="tab02">Tabela 2</xref> mostra as m&#233;dias press&#243;ricas obtidas pelos tr&#234;s m&#233;todos utilizados com as distin&#231;&#245;es para os per&#237;odos de registro da MAPA. J&#225; a <xref ref-type="table" rid="tab03">Tabela 3</xref> demonstra a correla&#231;&#227;o entre as diversas m&#233;dias entre si, com destaque para a compara&#231;&#227;o entre m&#233;dia de vig&#237;lia da MAPA e m&#233;dia da MRPA.</p>
    <table-wrap id="tab02">
      <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt02.jpg"/></table-wrap>
    <table-wrap id="tab03">
      <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt03.jpg"/></table-wrap>
    <p>A <xref ref-type="table" rid="tab04">Tabela 4</xref> compara o diagn&#243;stico da HAR feito pelos dois m&#233;todos avaliados. N&#227;o obstante a m&#233;dia sist&#243;lica da MRPA ter sido significantemente maior do que a m&#233;dia sist&#243;lica de vig&#237;lia da MAPA (<xref ref-type="table" rid="tab02">Tabela 2</xref>), o impacto na classifica&#231;&#227;o foi pequeno.</p>
    <table-wrap id="tab04">
      <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt04.jpg"/></table-wrap>
    <p>Em 19 pacientes (37,0%), a PA casual de consult&#243;rio esteve menos elevada do que aquelas obtidas na MAPA e MRPA. </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A distin&#231;&#227;o entre HA n&#227;o controlada por diversos fatores e a HA verdadeiramente resistente &#233; muito importante, pois os pacientes pertencentes ao primeiro grupo ser&#227;o submetidos, muitas vezes, a avalia&#231;&#245;es desnecess&#225;rias e a mudan&#231;as inconvenientes no regime de tratamento<sup>9</sup>. </p>
    <p>Embora o conceito de HAR seja arbitr&#225;rio, faz-se necess&#225;ria a identifica&#231;&#227;o de pacientes de alto risco que possam ter hipertens&#227;o de causas revers&#237;veis, separando-os daqueles que, em virtude dos elevados e persistentes n&#237;veis de PA, possam se beneficiar de medidas diagn&#243;sticas e terap&#234;uticas mais espec&#237;ficas que promovam melhor controle da doen&#231;a<sup>10</sup>.</p>
    <p>A MAPA &#233; considerada o padr&#227;o-ouro na confirma&#231;&#227;o da HAR<sup>11</sup>. Neste estudo, a MAPA detectou 33 pacientes com HAR e 18 com HA pseudorresistente. Entretanto, quando se considera a MRPA, a HAR foi diagnosticada em 37 casos. N&#227;o houve diferen&#231;a estatisticamente significante entre os dois m&#233;todos. Na realidade, constatou-se uma diferen&#231;a de 4 casos (8,0%), talvez configurando uma tend&#234;ncia mais favor&#225;vel &#224; MRPA, no que se refere &#224; sensibilidade diagn&#243;stica.</p>
    <p>A MRPA, quando comparada &#224; MAPA, apresenta algumas vantagens, principalmente em rela&#231;&#227;o ao custo e &#224; melhor ader&#234;ncia do paciente ao tratamento, apesar de n&#227;o avaliar as press&#245;es durante o sono<sup>12</sup>.</p>
    <p>Na correla&#231;&#227;o de Pearson, quando foram avaliadas a PAS e a PAD pela MAPA e MRPA, a associa&#231;&#227;o foi excelente, observando-se quase os mesmos valores e intervalos de confian&#231;a, o que revela a similaridade entre os dois exames. Al&#233;m disso, na diferen&#231;a entre os m&#233;todos, verificou-se que a MRPA diagnosticou mais a HAR (4 pacientes), como antes frisado. Esses poss&#237;veis casos falsos-positivos evidenciados pela MRPA, quando se considera a MAPA como padr&#227;o-ouro, s&#227;o de pequena express&#227;o, sem import&#226;ncia estat&#237;stica. Por&#233;m, vale ressaltar que diversos estudos mostraram melhores correla&#231;&#245;es das medidas press&#243;ricas da MRPA com as les&#245;es em &#243;rg&#227;os-alvo, em compara&#231;&#227;o com as medidas casuais de consult&#243;rio e da MAPA<sup>13,14</sup>.</p>
    <p>At&#233; hoje, os valores da MAPA foram refer&#234;ncias para a confirma&#231;&#227;o da hipertens&#227;o e sua classifica&#231;&#227;o. No entanto, a MRPA vem conquistando espa&#231;o por oferecer algumas das vantagens da MAPA, como n&#250;mero expressivo de medidas, detec&#231;&#227;o de HA do avental branco e efeito do avental branco<sup>15</sup>. Ademais, a MRPA pode aumentar a ades&#227;o &#224; terapia anti-hipertensiva e reduzir o n&#250;mero de consultas m&#233;dicas necess&#225;rias para o diagn&#243;stico, abreviando o tratamento da hipertens&#227;o, com consequente redu&#231;&#227;o nos custos e complica&#231;&#245;es deste processo. </p>
    <p>O estudo HOMERUS foi desenvolvido para determinar o quanto o tratamento baseado na MRPA poderia diminuir a prescri&#231;&#227;o de anti-hipertensivos desnecess&#225;rios e detectar les&#245;es em &#243;rg&#227;os-alvo, quando comparada &#224; medida casual do consult&#243;rio. O estudo demonstrou maior ajuste da terapia anti-hipertensiva baseada na MRPA, assim como maior controle dos pacientes com hipertens&#227;o refrat&#225;ria na compara&#231;&#227;o com a medida casual da PA<sup>16</sup>. </p>
    <p>Ao serem analisadas as diferen&#231;as entre as medidas casuais de consult&#243;rio, a MAPA na vig&#237;lia e a MRPA, observou-se que o desempenho dos m&#233;todos foi semelhante. Tais diferen&#231;as s&#227;o importantes na detec&#231;&#227;o do efeito do avental branco, quando a medida da PA no consult&#243;rio mostra-se mais elevada que na MAPA e/ou MRPA. </p>
    <p>Quanto ao fato de que, em 37,0% dos indiv&#237;duos (19 pacientes), a press&#227;o casual de consult&#243;rio estar mais baixa que na MAPA e MRPA, o estudo J-MORE denominou este fen&#244;meno de efeito do avental branco negativo, e concluiu que poderia estar relacionado &#224; idade mais elevada, sexo masculino e doen&#231;a card&#237;aca isqu&#234;mica<sup>17</sup>. No presente estudo, esse fen&#244;meno esteve presente em 11 homens, sendo que 31,0% destes apresentavam doen&#231;a coronariana associada.</p>
    <p>Em rela&#231;&#227;o &#224; obesidade, quando se analisa sua presen&#231;a ou n&#227;o, e a rela&#231;&#227;o com a HAR ou pseudorresistente, n&#227;o se obteve diferen&#231;a estatisticamente significante.</p>
    <p>V&#225;rios estudos citam as vantagens da MRPA. No entanto, Van der Hoeven e cols.<sup>18</sup> concluem em seu trabalho a import&#226;ncia de orienta&#231;&#227;o adequada e acompanhamento dos pacientes na realiza&#231;&#227;o da MRPA. Em estudo com 106 pacientes, os autores verificaram que mesmo com aparelhos equipados com mem&#243;ria para garantir a acur&#225;cia de data, hora e n&#250;mero de medidas, os envolvidos encontraram dificuldades<sup>18</sup>. </p>
    <p>No presente estudo, al&#233;m das orienta&#231;&#245;es verbais, os pacientes receberam uma cartilha e um n&#250;mero de telefone m&#243;vel que poderia ser utilizado a qualquer hora para resolu&#231;&#227;o de problemas ou d&#250;vidas. Observou-se que tal procedimento despertou o interesse e o comprometimento dos participantes, facilitando o entendimento, a ades&#227;o e o estreitamento do v&#237;nculo com o profissional de sa&#250;de.</p>
    <p>Alguns trabalhos trazem a MRPA associada ao telemonitoramento da PA, que consiste em sua aferi&#231;&#227;o domiciliar com o monitoramento e manejo remotos atrav&#233;s da transmiss&#227;o de dados por telefone ou pela internet. </p>
    <p>Os estudos nesta &#225;rea ainda s&#227;o escassos. Por&#233;m, alguns resultados preliminares t&#234;m se mostrado promissores<sup>19-21</sup>. </p>
    <p>Com base nos resultados obtidos, pode-se vislumbrar a MRPA como uma ferramenta muito &#250;til tamb&#233;m no diagn&#243;stico da verdadeira HAR, com reflexos altamente positivos na ades&#227;o do paciente hipertenso &#224; terap&#234;utica preconizada.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de disserta&#231;&#227;o de Mestrado de Fabiane Rosa R. H. Marui pela UNIFESP.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Francisco de Assis Costa </p>
        <p> Av. Fernandes Lima Km 5 - Farol - Hospital do A&#231;ucar - Farol </p>
        <p> 57055-000 - Macei&#243;, AL - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="facosta@cardiol.br">facosta@cardiol.br</email>, </p>
        <p>
          <email xlink:href="fcostahemo@hotmail.com">fcostahemo@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 18/11/09; revisado recebido em 03/02/10; aceito em 15/03/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007; 167 (2): 141-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>141</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>167</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>YR</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Stafford</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Sociedade Brasileira de Cardiologia. Sociedade Brasileira de Hipertens&#227;o. Sociedade Brasileira de Nefrologia. V Diretrizes brasileiras de hipertens&#227;o arterial. Arq Bras Cardiol. 2007; 89 (3): e24-79.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>V Diretrizes brasileiras de hipertens&#227;o arterial</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>e24</fpage>
          <lpage>79</lpage>
          <issue>3</issue>
          <volume>89</volume>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 342 (6): 1206-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title>
          <source>Hypertension</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1206</fpage>
          <lpage>52</lpage>
          <issue>6</issue>
          <volume>342</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chobanian</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Bakris</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Izzo Jr</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Calhoun DA, Jones D, Textor S, Goff DL, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117 (25): e510-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Resistant hypertension: diagnosis, evaluation, and treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research</article-title>
          <source>Circulation</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>e510</fpage>
          <lpage>26</lpage>
          <issue>25</issue>
          <volume>117</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Calhoun</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Textor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goff</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Toto</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Mezzetti A, Pierdomenico SD, Costantini F, Romano F, Bucc A, Di Giocchino M, et al. White-coat resistant hypertension. Am J Hypertens. 1997; 10 (11): 1302-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>White-coat resistant hypertension</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1302</fpage>
          <lpage>7</lpage>
          <issue>11</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mezzetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pierdomenico</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Costantini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bucc</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Di Giocchino</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Veglio F, Rabbia F, Riva P, Martini G, Genova GC, Milan A, et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens. 2001; 23 (3): 203-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension</article-title>
          <source>Clin Exp Hypertens</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>203</fpage>
          <lpage>11</lpage>
          <issue>3</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Veglio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rabbia</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Riva</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Genova</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Milan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Obara T, Ohkubo T, Funahashi J, Kikuya M, Asayama K, Metoki H, et al. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. J Hypertens. 2005; 23 (9): 1653-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1653</fpage>
          <lpage>60</lpage>
          <issue>9</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Obara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohkubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Funahashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kikuya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Asayama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Metoki</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Sociedade Brasileira de Cardiologia. IV Diretriz para o uso da monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial. II Diretriz para o uso da monitoriza&#231;&#227;o residencial da press&#227;o arterial. IV MAPA / II MRPA. Arq Bras Cardiol. 2005; 85 (supl 2): 1-18.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Diretriz para o uso da monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial: II Diretriz para o uso da monitoriza&#231;&#227;o residencial da press&#227;o arterial. IV MAPA / II MRPA</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1</fpage>
          <lpage>18</lpage>
          <volume>85</volume>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Fukunaga H, Ohkubo T, Kobayashi M, Tamakiu Y, Kikuya M, Obara T, et al. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. J Hypertens. 2008; 26 (4): 685-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>685</fpage>
          <lpage>90</lpage>
          <issue>4</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fukunaga</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ohkubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tamakiu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kikuya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Obara</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Hern&#225;ndez-del Rey R, Armario P, Martin-Baranera M, S&#225;nchez P, Cardenas G, Pardell H. Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect. Blood Press Monit. 1998; 3 (6): 331-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Target-organ damage and cardiovascular risk profile in resistant hypertension: Influence of the white-coat effect</article-title>
          <source>Blood Press Monit</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>331</fpage>
          <lpage>7</lpage>
          <issue>6</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hern&#225;ndez-del Rey</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Armario</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martin-Baranera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>S&#225;nchez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cardenas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pardell</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Lloyd-Jones DM, Evans JC, Larson MG, O' Donnel CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: associated with lack of blood pressure control in the community. Hypertension. 2000; 36 (4): 594-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Differential control of systolic and diastolic blood pressure: associated with lack of blood pressure control in the community</article-title>
          <source>Hypertension</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>594</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lloyd-Jones</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>O' Donnel</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Roccella</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008; 299 (24): 2857-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial</article-title>
          <source>JAMA</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>2857</fpage>
          <lpage>67</lpage>
          <issue>24</issue>
          <volume>299</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Ralston</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Fishman</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Catz</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Stergiou GS, Argyraki KK, Moyssakis I, Mastorantonakis SE, Archimastos AD, Karamanos VG, et al. Home blood pressure is a reliable as ambulatory blood pressure in predicting target-organ damage in hypertension. Am J Hypertens. 2007; 20 (6): 616-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Home blood pressure is a reliable as ambulatory blood pressure in predicting target-organ damage in hypertension</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>616</fpage>
          <lpage>21</lpage>
          <issue>6</issue>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stergiou</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Argyraki</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Moyssakis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mastorantonakis</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Archimastos</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Karamanos</surname>
              <given-names>VG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Gomes MAM, Pierin AMG, Segre CA, Mion Jr D. Monitoriza&#231;&#227;o residencial da press&#227;o arterial e monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial versus medida da press&#227;o arterial no consult&#243;rio. Arq Bras Cardiol. 1998; 71 (4): 581-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Monitoriza&#231;&#227;o residencial da press&#227;o arterial e monitoriza&#231;&#227;o ambulatorial da press&#227;o arterial versus medida da press&#227;o arterial no consult&#243;rio</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>581</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gomes</surname>
              <given-names>MAM</given-names>
            </name>
            <name>
              <surname>Pierin</surname>
              <given-names>AMG</given-names>
            </name>
            <name>
              <surname>Segre</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Mion Jr</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Rogers MA, Small D, Buchan DA, Butch CA, Stewart CM, Krenzer BE, et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension: a randomized controlled trial. Ann Intern Med. 2001; 134 (11): 1024-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Home monitoring service improves mean arterial pressure in patients with essential hypertension: a randomized controlled trial</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1024</fpage>
          <lpage>32</lpage>
          <issue>11</issue>
          <volume>134</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Small</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Buchan</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Butch</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Krenzer</surname>
              <given-names>BE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Clement DL, Buyzere ML, Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003; 348 (24): 2407-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2407</fpage>
          <lpage>15</lpage>
          <issue>24</issue>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Clement</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Buyzere</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Bacquer</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>de Leeuw</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Duprez</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Fagard</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Kabutoya T, Ishikawa J, Hoshide S, Eguchi K, Ishikawa S, Shimada K, et al. Determinants of negative white-coat effect in treated hypertensive patients: the Jichi Morning Hypertension Research (J-MORE) study. Am J Hypertens. 2009; 22 (1): 35-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determinants of negative white-coat effect in treated hypertensive patients: the Jichi Morning Hypertension Research (J-MORE) study</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>35</fpage>
          <lpage>40</lpage>
          <issue>1</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kabutoya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hoshide</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Eguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Van der Hoeven NV, Van der Born BJ, Cammenga M, Van Montfrans GA. Poor adherence to home blood pressure measurement schedule. J Hypertens. 2009; 27 (2): 275-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Poor adherence to home blood pressure measurement schedule</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>275</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Van der Hoeven</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Van der Born</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Cammenga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Van Montfrans</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens. 1996; 9 (4 Pt 1): 285-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A telecommunications system for monitoring and counseling patients with hypertension: Impact on medication adherence and blood pressure control</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>285</fpage>
          <lpage>92</lpage>
          <issue>4 Pt 1</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Friedman</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Kazis</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Jette</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Stollerman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Torgerson</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Artinian NT, Washington OG, Templin TN. Effects of home telemonitoring and community-based monitoring on blood pressure control in urban African Americans: a pilot study. Heart Lung. 2001; 30 (3): 191-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of home telemonitoring and community-based monitoring on blood pressure control in urban African Americans: a pilot study</article-title>
          <source>Heart Lung</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>191</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Artinian</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Washington</surname>
              <given-names>OG</given-names>
            </name>
            <name>
              <surname>Templin</surname>
              <given-names>TN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Ewald S, Vor dem Esche J, Uen S, Neikes F, Vetter H, Mengden T. Relationship between the frequency of blood pressure self measurement and blood pressure reduction with antihypertensive therapy: results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study. Clin Drug Investig. 2006; 26 (8): 439-46.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relationship between the frequency of blood pressure self measurement and blood pressure reduction with antihypertensive therapy: results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study</article-title>
          <source>Clin Drug Investig</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>439</fpage>
          <lpage>46</lpage>
          <issue>8</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ewald</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vor dem Esche</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Uen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Neikes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vetter</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mengden</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Assessment of resistant hypertension with home blood pressure monitoring</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Ambulatory blood pressure monitoring (ABPM) is considered the gold standard for the diagnostic confirmation of resistant hypertension (RH). However, home blood pressure monitoring (HBPM) has been considered an option, because of its lower cost and greater comfort. OBJECTIVE: To compare the values obtained by HBPM with those obtained by ABPM in the identification of patients with resistant hypertension. METHODS: A total of 51 consecutive patients with resistant hypertension were selected. All were adults of both genders and were undergoing treatment in an outpatient referral clinic from January 2007 to September 2009. Casual office blood pressure (BP), 24-hour ABPM, and HBPM were performed according to current guidelines, with a maximum two-week interval between the methods. RESULTS: The comparison of ABPM (mean daytime) with HBPM showed a good correlation between them, both for systolic blood pressure (SBP) and for diastolic blood pressure (DBP): SBP r = 0.70, CI = 0.51-0.82, DBP r = 0.69, CI = 0.52-0.81. RH was confirmed by ABPM in 33 patients and by HBPM in 37, with no significant difference between the methods. CONCLUSION: According to the results obtained, we conclude that HBPM is a method that can be used as an alternative to ABPM for the diagnostic confirmation of RH.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Hypertension</kwd>
        <kwd>blood pressure monitoring, ambulatory</kwd>
        <kwd>blood pressure</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="tx-body2">
          <label>
            <bold>Assessment of resistant hypertension with home blood pressure monitoring</bold>
          </label>
          <p>
            <bold>Fabiane Rosa Rezende H. Marui; Maria Teresa Nogueira Bombig; Yon&#225; Afonso Francisco; Jos&#233; Marcos Thalenberg; Francisco Antonio Helfenstein Fonseca; Dilma de Souza; Francisco de Assis Costa; Maria Cristina Izar; Antonio Carlos de Camargo Carvalho; Rui P&#243;voa</bold>
          </p>
        </fn>
      </p>
      <p> Universidade Federal de S&#227;o Paulo - Escola Paulista de Medicina, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Ambulatory blood pressure monitoring (ABPM) is considered the gold standard for the diagnostic confirmation of resistant hypertension (RH). However, home blood pressure monitoring (HBPM) has been considered an option, because of its lower cost and greater comfort.</p>
      <p><bold>OBJECTIVE:</bold> To compare the values obtained by HBPM with those obtained by ABPM in the identification of patients with resistant hypertension.</p>
      <p><bold>METHODS:</bold> A total of 51 consecutive patients with resistant hypertension were selected. All were adults of both genders and were undergoing treatment in an outpatient referral clinic from January 2007 to September 2009. Casual office blood pressure (BP), 24-hour ABPM, and HBPM were performed according to current guidelines, with a maximum two-week interval between the methods.</p>
      <p><bold>RESULTS:</bold> The comparison of ABPM (mean daytime) with HBPM showed a good correlation between them, both for systolic blood pressure (SBP) and for diastolic blood pressure (DBP): SBP r = 0.70, CI = 0.51-0.82, DBP r = 0.69, CI = 0.52-0.81. RH was confirmed by ABPM in 33 patients and by HBPM in 37, with no significant difference between the methods.</p>
      <p><bold>CONCLUSION:</bold> According to the results obtained, we conclude that HBPM is a method that can be used as an alternative to ABPM for the diagnostic confirmation of RH. </p>
      <p><bold>Key words:</bold> Hypertension; blood pressure monitoring, ambulatory; blood pressure/drug effects.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Hypertension has a high prevalence in Brazil with a very high medical and socioeconomic burden given its resulting complications. BP reduction decreases the risk of development of these complications; however, BP control is only achieved in a minority of the hypertensive patients<sup>1</sup>. In Brazil, only 10.0% of the hypertensive population is estimated to have a controlled BP, whether because of a missing diagnosis, lack of treatment, or difficulties to control the disease<sup>2</sup>. Resistant hypertension may be present in as much as 20.0% to 40.0% of the hypertensive individuals<sup>3</sup>.</p>
      <p>RH is defined by the finding of casual office BP levels that remain above goal in patients taking at least three antihypertensive agents of different classes, including a diuretic whenever possible, at optimal doses<sup>4</sup>. </p>
      <p>Several factors influence the identification of RH, such as a poor technique for BP measurement, poor adherence to treatment, and BP elevation only in a medical environment (white coat effect)<sup>4</sup>. These factors may lead to pseudoresistance, which is an apparent lack of BP control when measured in a medical office. If the technique and adherence are adequate, but the white coat effect changes the diagnosis, the white coat RH syndrome is characterized<sup>5</sup>. The only means to correctly identify this condition is by using BP monitoring<sup>6</sup>.</p>
      <p>ABPM, considered the gold standard for the diagnostic confirmation of RH, is still an expensive procedure unfeasible for the majority of the population. However, HBPM has been widely studied because it is easy to apply and has good patient acceptability<sup>7</sup>. Thus, the objective of this study was to compare the values obtained by HBPM with those obtained by ABPM, thus analyzing the validity of the method in the identification of resistant hypertensive patients.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Patients</bold>
      </p>
      <p>A total of 51 consecutive hypertensive patients were selected. They were using at least three classes of antihypertensive medications at optimal doses, including a diuretic, and were being treated in the Department of Hypertensive Heart Disease of <italic>Universidade Federal de S&#227;o Paulo</italic> - UNIFESP, from January 2007 to September 2009. </p>
      <p>The Research Ethics Committee approved the research protocol and all patients gave written informed consent, according to the principles of the Declaration of Helsinki.</p>
      <p>Patients presenting with office SBP <underline>&gt;</underline> 140 mmHg and/or DBP <underline>&gt;</underline> 90 mmHg (or <underline>&gt;</underline> 130 x 80 mmHg for diabetic patients and patients with renal injury) were included. The mean of two out of three measurements taken in both upper limbs (using the measurement of the limb where the highest values were obtained) was considered. Secondary hypertension was systematically investigated in the patients by means of a standard screening according to the protocol used in the Department, which is based on the first American Heart Association guideline on RH<sup>6</sup>. </p>
      <p>Full clinical assessment of all patients was performed, including information on medications used and factors related to the lifestyle, such as cigarette smoking and alcohol consumption, as well as the regular practice of physical activity. Anthropometric measurements were taken including height, weight, and waist and hip circumferences. Routine laboratory tests were used to investigate diabetes or renal injury.</p>
      <p>For casual office BP measurement, the auscultatory method with a mercury-column sphygmomanometer was used. Three measurements were taken in each arm, at 1-minute intervals between measurements, with the patient in the sitting position and resting for 5 minutes. The mean of the last two measurements in the limb showing the highest values was considered<sup>2</sup>. </p>
      <p>Next, ABPM and HBPM were scheduled. The ABPM monitors (Spacelabs 90207&#8482;) were programmed to take BP every 15 minutes (daytime) and every 30 minutes (nightime) for 24 hours, with a proper cuff positioned in the non-dominant arm. Nightime and daytime were set individually and checked according to the daily recordings. </p>
      <p>As regards HBPM, three BP measurements were taken in the morning and at night for five consecutive days, with the first day reserved for instructions, according to the IV Guideline for the Use of Ambulatory Blood Pressure Monitoring and the II Guideline for the Use of Home Blood Pressure Monitoring of the Brazilian Society of Cardiology<sup>8</sup>. In addition to verbal instructions, the participants also received a handout describing the methods. A validated semi-automated device (Microlife BP 3AC1-1&#8482;) was used. The time elapsed between the casual office measurement and ABPM and HBPM installation was not longer than two weeks. </p>
      <p>
        <bold>Diagnostic criteria</bold>
      </p>
      <p>For casual BP measurement, SBP values <underline>&gt;</underline> 140 mmHg and/or DBP <underline>&gt;</underline> 90 mmHg (or <underline>&gt;</underline> 130 mmHg and/or 80 mmHg for patients with diabetes and patients with renal injury) were considered RH. For ABPM, mean daytime values <underline>&gt;</underline> 135 mmHg (SBP) or <underline>&gt;</underline> 85 mmHg (DBP) were considered for the diagnosis of RH; the same values applied to HBPM in properly medicated patients.</p>
      <p>The diagnosis of diabetes mellitus was made for patients with fasting plasma glucose levels <underline>&gt;</underline> 126 mg/dl or for those receiving treatment for this disease. The diagnosis of renal injury was based on a glomerular filtration rate &lt; 60 ml/min/1.73 m<sup>2</sup>, as estimated by the Cockcroft-Gault formula.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>The results were expressed as means and standard deviation. The chi square test and Pearson's linear correlation were used for result analysis. The level of statistical significance was set at 95% confidence intervals and p &lt; 0.05. </p>
      <p>
        <bold>Results</bold>
      </p>
      <p>A total of 28 men (55.0%) and 23 women (45.0%) with ages between 34 and 74 years (mean of 56.4 &#177; 10 years) participated in the study. The characteristics of the study population as regards the anthropometric data and the presence of cardiovascular risk factors are summarized in <xref ref-type="table" rid="tab01-body2">Table 1</xref>. A significant incidence of overweight and obesity (84% of the sample) was observed, with six patients presenting with body mass index (BMI) <underline>&gt;</underline> 40 (morbid obesity). Only five men and one woman had an adequate waist-hip ratio (<underline>&lt;</underline> 0.90 and 0.85, respectively). As regards the patients reporting the presence of snoring during sleep (61.0% of the sample), all had a BMI <underline>&gt;</underline> 25.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt01-en.jpg"/></table-wrap>
      <p>The antihypertensive medications most frequently prescribed were: thiazides (hydrochlorothiazide, with 34 prescriptions; and chlorthalidone, with 17 prescriptions), captopril (24 prescriptions), amlodipine (36 prescriptions), and propranolol (22 prescriptions). In addition to these medications, 22 patients were receiving antiplatelet agents.</p>
      <p>The mean blood pressure levels obtained by the three methods used with discrimination of the periods of ABPM recordings are shown in <xref ref-type="table" rid="tab02-body2">Table 2</xref>. The correlation between the different means, with emphasis on the comparison between mean daytime ABPM and mean HBPM are shown in <xref ref-type="table" rid="tab03-body2">Table 3</xref>. </p>
      <table-wrap id="tab02-body2">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt02-en.jpg"/></table-wrap>
      <table-wrap id="tab03-body2">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt03-en.jpg"/></table-wrap>
      <p>The comparison of the diagnosis of RH as made by the two methods analyzed is shown in <xref ref-type="table" rid="tab04-body2">Table 4</xref>. Although the mean systolic BP, as determined by HBPM, was significantly higher than the mean daytime systolic BP by ABPM (<xref ref-type="table" rid="tab02-body2">Table 2</xref>), the impact of this difference on classification was small. </p>
      <table-wrap id="tab04-body2">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt04-en.jpg"/></table-wrap>
      <p>Casual office BP was less elevated than those obtained by ABPM and HBPM in 19 patients (37.0%). </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Distinction between uncontrolled hypertension due to different factors and true resistant hypertension is very important, because patients belonging to the first group are frequently subjected to unnecessary tests and inconvenient changes in their treatment regimens<sup>9</sup>. </p>
      <p>Although the concept of RH is arbitrary, it is necessary to identify patients who are at high risk of having reversible causes of hypertension, and separate them from those who, because of persistently high BP levels, may benefit from more specific diagnostic and therapeutic measures that promote a better control of their disease<sup>10</sup>. </p>
      <p>ABPM is considered the gold standard for the confirmation of RH<sup>11</sup>. In this study, ABPM detected 33 patients with RH and 18 with pseudoresistant hypertension. However, using HBPM, 37 cases were diagnosed with RH. There was no statistically significant difference between the two methods. As a matter of fact, a difference of four cases (8.0%) was observed, perhaps pointing to a tendency of a more favorable performance of HBPM as regards diagnostic sensitivity. </p>
      <p>In comparison to ABPM, HBPM has some advantages, especially in relation to costs and to a better patient adherence to treatment, although it does not evaluate pressures during sleep<sup>12</sup>.</p>
      <p>The Pearson correlation showed an excellent association when SBP and DBP as measured by ABPM and HBPM were analyzed, and almost the same values and confidence intervals were observed, which shows the similarity between the two methods. In relation to the differences between the two methods, it was verified that HBPM diagnosed more cases of RH (4 patients), as was previously stressed. This number of possibly false-positive cases evidenced by HBPM is not expressive and has no statistical significance when ABPM is taken as the gold standard. However, we should point out that several studies have shown better correlations between blood pressure measurements taken using HBPM and target-organ lesions in comparison to casual office measurements and those taken using ABPM<sup>13,14</sup>.</p>
      <p>To date, ABPM values have been the reference for the confirmation and classification of hypertension. However, HBPM has gained ground because it provides some of ABPM advantages, such as an expressive number of measurements, and detection of white-coat hypertension and white-coat effect<sup>15</sup>. Furthermore, HBPM may increase the adherence to antihypertensive therapy and reduce the number of medical visits required for the diagnosis, thus abbreviating the treatment of hypertension, with the subsequent reduction in costs and complications of this process.</p>
      <p>The HOMERUS study was designed to determine the impact of treatments based on HBPM on the reduction of unnecessary prescriptions of antihypertensive drugs and on the detection of target-organ lesions in comparison to those based on casual office BP measurement. The study demonstrated a better adjustment of the antihypertensive therapy based on HBPM, as well as a better control of patients with refractory hypertension in comparison to treatment based on casual BP measurement<sup>16</sup>. </p>
      <p>The analysis of the differences between casual office measurements, daytime ABPM and HBPM showed that the performance of the three methods was similar. These differences are important in the detection of the white-coat effect, when office BP measurement is higher than that obtained with ABPM and/or HBPM.</p>
      <p>As regards the fact that 37.0% of the individuals (19 patients) had casual office BP measurements lower than in ABPM and HBPM, the J-MORE study named this phenomenon as negative white-coat effect, and concluded that it could be related to aging, male gender, and ischemic heart disease<sup>17</sup>. In the present study, this phenomenon was observed in 11 men, 31.0% of whom had associated coronary artery disease.</p>
      <p>In relation to the presence or absence of obesity and its relation to RH or pseudoresistant hypertension, no statistically significant difference was found. </p>
      <p>Several studies describe the advantages of HBPM. However, Van der Hoeven et al<sup>18</sup> studied 106 patients undergoing HBPM and concluded that they need proper instruction and a close watch. The authors verified that even using memory-equipped devices to ensure the accuracy of date, time and number of measurements, the participants had difficulties with the method<sup>18</sup>.</p>
      <p>In the present study, in addition to verbal instructions, the patients received a handout and a mobile phone number which they could call at any time to solve problems or questions. We observed that this procedure aroused the participants' interest and commitment, thus facilitating their understanding, adherence and relationship with the health professional. </p>
      <p>Some studies associated HBPM with BP telemonitoring, which consists of home BP measurement with remote monitoring and management using data transmission by telephone or over the Internet. </p>
      <p>Few studies in this area are available. However, some preliminary results have been encouraging<sup>19-21</sup>.</p>
      <p>Based on the results obtained, we can anticipate HBPM as a very useful tool in the diagnosis of true RH with highly positive reflexes on hypertensive patients' adherence to the treatment established. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of master submitted by Fabiane Rosa R. H. Marui, from UNIFESP.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Evaluaci&#243;n de la hipertensi&#243;n arterial resistente por monitoreo residencial de la presi&#243;n arterial</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El monitoreo ambulatorio de la presi&#243;n arterial (MAPA) es considerado el gold standard para la confirmaci&#243;n diagn&#243;stica de la hipertensi&#243;n arterial resistente (HAR). Mientras tanto, el monitoreo residencial de la presi&#243;n arterial (MRPA) ha sido considerado una opci&#243;n, por su costo menor y mayor confort. OBJETIVO: Comparar los valores obtenidos por la MRPA con los obtenidos por la MAPA en la identificaci&#243;n de pacientes hipertensos resistentes. M&#201;TODOS: Fueron seleccionados consecutivamente 51 pacientes hipertensos resistentes, adultos de ambos sexos, en tratamiento ambulatorio de referencia, de ene/2007-set/2009. La medida de la presi&#243;n arterial (PA) casual de consultorio, MAPA de 24 horas y MRPA fueron realizadas seg&#250;n las directrices vigentes, con intervalo m&#225;ximo de dos semanas entre los m&#233;todos. RESULTADOS: Al comparar la MAPA (media de vigilia) y MRPA, fue obtenida buena correlaci&#243;n entre ambas, tanto para la presi&#243;n arterial sist&#243;lica (PAS) como para la diast&#243;lica (PAD): PAS r = 0,70, IC = 0,51-0,82; PAD r = 0,69, IC = 0,52-0,81. La HAR fue confirmada por la MAPA en 33 pacientes y por la MRPA en 37 de esos, no habiendo diferencia significativa entre los dos m&#233;todos. CONCLUSI&#211;N: De acuerdo con los resultados obtenidos, se concluye que la MRPA es un examen que puede ser utilizado como alternativa a la MAPA para la confirmaci&#243;n diagn&#243;stica de la HAR.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Hipertensi&#243;n</kwd>
        <kwd>monitoreo ambulatorio de la presi&#243;n arterial</kwd>
        <kwd>presi&#243;n arterial</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Evaluaci&#243;n de la hipertensi&#243;n arterial resistente por monitoreo residencial de la presi&#243;n arterial</bold>
          </label>
          <p>
            <bold>Fabiane Rosa Rezende H. Marui; Maria Teresa Nogueira Bombig; Yon&#225; Afonso Francisco; Jos&#233; Marcos Thalenberg; Francisco Antonio Helfenstein Fonseca; Dilma de Souza; Francisco de Assis Costa; Maria Cristina Izar; Antonio Carlos de Camargo Carvalho; Rui P&#243;voa</bold>
          </p>
        </fn>
      </p>
      <p>Universidade Federal de S&#227;o Paulo - Escola Paulista de Medicina, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> El monitoreo ambulatorio de la presi&#243;n arterial (MAPA) es considerado el <italic>gold standard</italic> para la confirmaci&#243;n diagn&#243;stica de la hipertensi&#243;n arterial resistente (HAR). Mientras tanto, el monitoreo residencial de la presi&#243;n arterial (MRPA) ha sido considerado una opci&#243;n, por su costo menor y mayor confort.</p>
      <p><bold>OBJETIVO:</bold> Comparar los valores obtenidos por la MRPA con los obtenidos por la MAPA en la identificaci&#243;n de pacientes hipertensos resistentes.</p>
      <p><bold>M&#201;TODOS:</bold> Fueron seleccionados consecutivamente 51 pacientes hipertensos resistentes, adultos de ambos sexos, en tratamiento ambulatorio de referencia, de ene/2007-set/2009. La medida de la presi&#243;n arterial (PA) casual de consultorio, MAPA de 24 horas y MRPA fueron realizadas seg&#250;n las directrices vigentes, con intervalo m&#225;ximo de dos semanas entre los m&#233;todos.</p>
      <p><bold>RESULTADOS:</bold> Al comparar la MAPA (media de vigilia) y MRPA, fue obtenida buena correlaci&#243;n entre ambas, tanto para la presi&#243;n arterial sist&#243;lica (PAS) como para la diast&#243;lica (PAD): PAS r = 0,70, IC = 0,51-0,82; PAD r = 0,69, IC = 0,52-0,81. La HAR fue confirmada por la MAPA en 33 pacientes y por la MRPA en 37 de esos, no habiendo diferencia significativa entre los dos m&#233;todos.</p>
      <p><bold>CONCLUSI&#211;N:</bold> De acuerdo con los resultados obtenidos, se concluye que la MRPA es un examen que puede ser utilizado como alternativa a la MAPA para la confirmaci&#243;n diagn&#243;stica de la HAR.</p>
      <p><bold>Palabras clave:</bold> Hipertensi&#243;n, monitoreo ambulatorio de la presi&#243;n arterial, presi&#243;n arterial/efectos de drogas.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La hipertensi&#243;n arterial (HA) tiene alta prevalencia en el Brasil y presenta costos m&#233;dicos y socioecon&#243;micos muy elevados, dadas las complicaciones que ocasiona. La reducci&#243;n de la PA disminuye los riesgos de aparici&#243;n de tales complicaciones, sin embargo su control s&#243;lo es conseguido en una minor&#237;a de los pacientes hipertensos<sup>1</sup>. En el Brasil, se estima que apenas 10,0% de la poblaci&#243;n hipertensa est&#233; con PA controlada, sea por falta de diagn&#243;stico, de tratamiento, o sea por dificultades en el control de la enfermedad<sup>2</sup>. La resistencia al tratamiento de la HA puede estar presente en 20,0% a 40,0% de los hipertensos<sup>3</sup>.</p>
      <p>LA HAR es definida por la constataci&#243;n de valores de la PA casual en consultorio persistentemente encima de las metas de control en paciente usando por lo menos tres clases de antihipertensivos, incluyendo un diur&#233;tico siempre que sea posible, en dosajes optimizados<sup>4</sup>.</p>
      <p>Varios factores influyen en la identificaci&#243;n de la HAR, tales como: t&#233;cnica incorrecta de medida de la PA, baja adhesi&#243;n al tratamiento y elevaci&#243;n de la PA apenas en ambiente m&#233;dico (efecto del guardapolvo blanco)<sup>4</sup>. Esos factores pueden llevar a la "pseudorresistencia", que es una aparente falta de control de la PA cuando es verificada en consultorio. Si la t&#233;cnica y la adhesi&#243;n son satisfactorias, pero el efecto del guardapolvo blanco altera el diagn&#243;stico, se configura la llamada HAR del guardapolvo branco<sup>5</sup>. La &#250;nica forma de identificar correctamente esta condici&#243;n es por medio de los monitoreos de la PA<sup>6</sup>.</p>
      <p>La MAPA, considerada el <italic>gold standard</italic> para la confirmaci&#243;n diagn&#243;stica de la HAR, aun es un procedimiento caro y no aplicable a la mayor&#237;a de la poblaci&#243;n. Mientras tanto, la MRPA ha sido ampliamente estudiada, pues se trata de un examen de f&#225;cil aplicaci&#243;n y buena aceptabilidad por los pacientes<sup>7</sup>. As&#237;, el objetivo de esta investigaci&#243;n fue comparar los valores obtenidos por la MRPA con aquellos obtenidos por la MAPA, midi&#233;ndose la validez del m&#233;todo en la identificaci&#243;n de pacientes hipertensos resistentes.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Pacientes</bold>
      </p>
      <p>Fueron seleccionados consecutivamente 51 pacientes hipertensos, en uso de por lo menos tres clases de antihipertensivos en dosajes optimizadas, siendo uno de ellos un diur&#233;tico, en tratamiento en el Sector de Cardiopat&#237;a Hipertensiva de la Universidad Federal de S&#227;o Paulo - UNIFESP, en el per&#237;odo de ene/2007-set/2009.</p>
      <p>El Comit&#233; de &#201;tica en Investigaci&#243;n aprob&#243; el protocolo de investigaci&#243;n y todos los pacientes firmaron el t&#233;rmino de consentimiento libre y aclarado, de acuerdo con los principios de la Declaraci&#243;n de Helsinki.</p>
      <p>En el estudio, fueron incluidos pacientes que presentaron PAS <underline>&gt;</underline> 140 mmHg y/o PAD <underline>&gt;</underline> 90 mmHg en el consultorio (o <underline>&gt;</underline> 130/80 mmHg en diab&#233;ticos y en pacientes con lesi&#243;n renal), consider&#225;ndose la media de dos de las tres medidas realizadas en ambos miembros superiores (tenidas en cuenta las medidas del miembro con valores m&#225;s elevados). La hipertensi&#243;n secundaria fue sistem&#225;ticamente investigada en los pacientes, utiliz&#225;ndose rastreo estandarizado seg&#250;n protocolo usado en el Sector, basado en la primera directriz de la <italic>American Heart Association</italic> sobre HAR<sup>6</sup>.</p>
      <p>Una evaluaci&#243;n cl&#237;nica completa de los pacientes fue realizada, incluyendo los medicamentos en uso y factores relacionados al estilo de vida, como consumo de alcohol y tabaquismo, as&#237; como pr&#225;ctica habitual de actividad f&#237;sica. Fueron verificadas las medidas antropom&#233;tricas, que constaron de altura, peso, circunferencia abdominal y de la cadera. Para la determinaci&#243;n de diabetes o lesi&#243;n renal, fue utilizada evaluaci&#243;n de laboratorio de rutina.</p>
      <p>Para la medida de la PA casual de consultorio, fue utilizado el m&#233;todo auscultatorio con esfigmoman&#243;metro de columna de mercurio. Fueron realizadas tres medidas en cada brazo, con un intervalo de un minuto entre las medidas, estando el paciente sentado y en reposo por 5 minutos. Se consider&#243; la media de las dos &#250;ltimas medidas en el miembro cuyos valores fueron los m&#225;s elevados<sup>2</sup>.</p>
      <p>A continuaci&#243;n, era ordenada la realizaci&#243;n de la MAPA y de la MRPA. Los monitores para MAPA (Spacelabs 90207<sup>&#174;</sup>) fueron programados para medir la PA, cada 15 minutos (vigilia) y cada 30 minutos (sue&#241;o) durante 24 horas, con manguito apropiado ubicado en el brazo no dominante. Los horarios de dormir y despertar fueron establecidos individualmente y chequeados de acuerdo con los registros del diario.</p>
      <p>En cuanto a la MRPA, fueron realizadas tres medidas de la PA por la ma&#241;ana y a la noche, durante 5 d&#237;as consecutivos, siendo el primer d&#237;a reservado para orientaciones, de acuerdo con la IV Directriz para Uso del Monitoreo Ambulatorio de la Presi&#243;n Arterial y II Directriz para Uso del Monitoreo Residencial de la Presi&#243;n Arterial de la <italic>Sociedade Brasileira de Cardiologia</italic><sup>8</sup>. Adem&#225;s de orientaci&#243;n verbal, el participante recibi&#243; una cartilla con la descripci&#243;n de los m&#233;todos. Fue utilizado aparato semiautom&#225;tico validado (Microlife BP 3AC1-1<sup>&#174;</sup>). El intervalo entre la medida casual de consultorio, la instalaci&#243;n de la MAPA y MRPA no fue superior a dos semanas.</p>
      <p>
        <bold>Criterios diagn&#243;sticos</bold>
      </p>
      <p>Para la medida de PA casual, se consideraron como HAR valores para la PAS <underline>&gt;</underline> 140 mmHg y/o para la PAD <underline>&gt;</underline> 90 mmHg (o <underline>&gt;</underline> 130 mmHg y/o 80 mmHg en diab&#233;ticos y en pacientes con lesi&#243;n renal). Para la MAPA, fueron consideradas las medias de vigilia <underline>&gt;</underline> 135 mmHg (PAS) o 85 mmHg (PAD), observ&#225;ndose las mismas cifras para la MRPA en pacientes debidamente medicados.</p>
      <p>El diagn&#243;stico de diabetes mellitus fue establecido para pacientes con glicemia de ayuno <underline>&gt;</underline> 126 mg/dL o en tratamiento para tal. Para lesi&#243;n renal, fue considerada tasa de filtraci&#243;n glomerular &lt; 60 ml/min/1,73 m<sup>2</sup>, estimada por la f&#243;rmula de Cockcroft-Gault.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los resultados fueron expresados en medias y desv&#237;o-est&#225;ndar. Fueron utilizados los test del qui-cuadrado y la correlaci&#243;n lineal de Pearson para el an&#225;lisis de los resultados. Para la verificaci&#243;n de significancia estad&#237;stica fueron considerados intervalos de confianza de 95,0% y p &lt; 0,05.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Participaron del estudio 28 hombres (55,0%) y 23 mujeres (45,0%), con edad entre 34-74 a&#241;os (media de 56,4 &#177; 10 a&#241;os). La <xref ref-type="table" rid="t1-body3">Tabla 1</xref> resume las caracter&#237;sticas de la poblaci&#243;n del estudio en cuanto a datos antropom&#233;tricos y la presencia de factores de riesgo cardiovascular. Se destaca la presencia de sobrepeso y obesidad (84,0% de la muestra), siendo que 6 pacientes ten&#237;an &#237;ndice de masa corporal (IMC) <underline>&gt;</underline> 40 (obesidad m&#243;rbida). Apenas 5 hombres y una mujer presentaron relaci&#243;n cintura-cadera adecuada (<underline>&lt;</underline> 0,90 y 0,85, respectivamente). En cuanto a aquellos que autorrefer&#237;an la presencia de ronquido durante el sue&#241;o (61,0% de la muestra), todos ten&#237;an IMC <underline>&gt;</underline> 25.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt01-es.jpg"/></table-wrap>
      <p>Las medicaciones antihipertensivas m&#225;s prescriptas fueron: tiaz&#237;dicos (hidroclorotiazida, con 34 prescripciones y clortalidona, con 17 prescripciones), captopril (24 prescripciones), amlodipina (36 prescripciones), propranolol (22 prescripciones). Adem&#225;s de esos, 22 pacientes hac&#237;an uso de antiagregantes plaquetarios.</p>
      <p>La <xref ref-type="table" rid="t2-body3">Tabla 2</xref> muestra las medias pres&#243;ricas obtenidas por los tres m&#233;todos utilizados con las distinciones para los per&#237;odos de registro de la MAPA. La <xref ref-type="table" rid="t3-body3">Tabla 3</xref> demuestra la correlaci&#243;n entre las diversas medias entre s&#237;, destac&#225;ndose la comparaci&#243;n entre media de vigilia de la MAPA y media de la MRPA.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt02-es.jpg"/></table-wrap>
      <table-wrap id="t3-body3">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt03-es.jpg"/></table-wrap>
      <p>La <xref ref-type="table" rid="t4-body3">Tabla 4</xref> compara el diagn&#243;stico de la HAR hecho por los dos m&#233;todos evaluados. No obstante la media sist&#243;lica de la MRPA haber sido significativamente mayor que la media sist&#243;lica de vigilia de la MAPA (<xref ref-type="table" rid="t2-body3">Tabla 2</xref>), el impacto en la clasificaci&#243;n fue peque&#241;o.</p>
      <table-wrap id="t4-body3">
        <graphic xlink:href="1678-4170-abc-95-04-0536-00120-gt04-es.jpg"/></table-wrap>
      <p>En 19 pacientes (37,0%), la PA casual de consultorio estuvo menos elevada que aquellas obtenidas en la MAPA y MRPA.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La distinci&#243;n entre HA no controlada por diversos factores y la HA verdaderamente resistente es muy importante, pues los pacientes pertenecientes al primer grupo ser&#225;n sometidos, muchas veces, a evaluaciones innecesarias y a cambios inconvenientes en el r&#233;gimen de tratamiento<sup>9</sup>.</p>
      <p>Aunque el concepto de HAR sea arbitrario, se hace necesaria la identificaci&#243;n de pacientes de alto riesgo que puedan tener hipertensi&#243;n de causas reversibles, separ&#225;ndolos de aquellos que, en virtud de los elevados y persistentes niveles de PA, puedan beneficiarse de medidas diagn&#243;sticas y terap&#233;uticas m&#225;s espec&#237;ficas que promuevan mejor control de la enfermedad<sup>10</sup>.</p>
      <p>LA MAPA es considerada el <italic>gold standard</italic> en la confirmaci&#243;n de la HAR<sup>11</sup>. En este estudio, la MAPA detect&#243; 33 pacientes con HAR y 18 con HA pseudorresistente. Mientras tanto, cuando se considera la MRPA, la HAR fue diagnosticada en 37 casos. No hubo diferencia estad&#237;sticamente significativa entre los dos m&#233;todos. En realidad, se constat&#243; una diferencia de 4 casos (8,0%), tal vez configurando una tendencia m&#225;s favorable a la MRPA, en lo que se refiere a la sensibilidad diagn&#243;stica.</p>
      <p>La MRPA, cuando es comparada a la MAPA, presenta algunas ventajas, principalmente en relaci&#243;n al costo y a la mejor adherencia del paciente al tratamiento, a pesar de no evaluar las presiones durante el sue&#241;o<sup>12</sup>.</p>
      <p>En la correlaci&#243;n de Pearson, cuando fueron evaluadas la PAS y la PAD por la MAPA y MRPA, la asociaci&#243;n fue excelente, observ&#225;ndose casi los mismos valores e intervalos de confianza, lo que revela la similitud entre los dos ex&#225;menes. Adem&#225;s de eso, en la diferencia entre los m&#233;todos, se verific&#243; que la MRPA diagnostic&#243; m&#225;s la HAR (4 pacientes), como fue se&#241;alado antes. Esos posibles casos falsos-positivos evidenciados por la MRPA, cuando se considera la MAPA como <italic>gold standard</italic>, son de peque&#241;a entidad, sin importancia estad&#237;stica. Sin embargo, vale resaltar que diversos estudios mostraron mejores correlaciones de las medidas pres&#243;ricas de la MRPA con las lesiones en org&#225;nos-blanco, en comparaci&#243;n con las medidas casuales de consultorio y de la MAPA<sup>13,14</sup>.</p>
      <p>Hasta hoy, los valores de la MAPA fueron referencias para la confirmaci&#243;n de la hipertensi&#243;n y su clasificaci&#243;n. Mientras tanto, la MRPA viene conquistando espacio por ofrecer algunas de las ventajas de la MAPA, como n&#250;mero significativo de medidas, detecci&#243;n de HA del guardapolvo blanco y efecto del guardapolvo blanco<sup>15</sup>. Adem&#225;s, la MRPA puede aumentar la adhesi&#243;n a la terapia antihipertensiva y reducir el n&#250;mero de consultas m&#233;dicas necesarias para el diagn&#243;stico, abreviando el tratamiento de la hipertensi&#243;n, con la consecuente reducci&#243;n en los costos y complicaciones de este proceso.</p>
      <p>El estudio HOMERUS fue desarrollado para determinar cuanto el tratamiento basado en la MRPA podr&#237;a disminuir la prescripci&#243;n de antihipertensivos innecesarios y detectar lesiones en &#243;rganos-blanco, cuando es comparada a la medida casual del consultorio. El estudio demostr&#243; mayor ajuste de la terapia antihipertensiva basada en la MRPA, as&#237; como mayor control de los pacientes con hipertensi&#243;n refractaria en la comparaci&#243;n con la medida casual de la PA<sup>16</sup>.</p>
      <p>Al ser analizadas las diferencias entre las medidas casuales de consultorio, la MAPA en la vigilia y la MRPA, se observ&#243; que el desempe&#241;o de los m&#233;todos fue semejante. Tales diferencias son importantes en la detecci&#243;n del efecto del guardapolvo blanco, cuando la medida de la PA en el consultorio se muestra m&#225;s elevada que en la MAPA y/o MRPA.</p>
      <p>En cuanto al hecho de que, en 37,0% de los individuos (19 pacientes), la presi&#243;n casual de consultorio estaba m&#225;s baja que en la MAPA y MRPA, el estudio J-MORE denomin&#243; este fen&#243;meno de efecto del guardapolvo blanco negativo, y concluy&#243; que podr&#237;a estar relacionado a la edad m&#225;s elevada, sexo masculino y enfermedad card&#237;aca isqu&#233;mica<sup>17</sup>. En el presente estudio, ese fen&#243;meno estuvo presente en 11 hombres, siendo que 31,0% de estos presentaban enfermedad coronaria asociada.</p>
      <p>En relaci&#243;n a la obesidad, cuando se analiza su presencia o no, y la relaci&#243;n con la HAR o pseudorresistente, no se obtuvo diferencia estad&#237;sticamente significativamente.</p>
      <p>Varios estudios citan las ventajas de la MRPA. Mientras tanto, Van der Hoeven et al<sup>18</sup> concluyen en su trabajo la importancia de la orientaci&#243;n adecuada y control de los pacientes en la realizaci&#243;n de la MRPA. En estudio con 106 pacientes, los autores verificaron que aun con aparatos equipados con memoria para garantizar la precisi&#243;n de fecha, hora y n&#250;mero de medidas, los participantes encontraron dificultades<sup>18</sup>.</p>
      <p>En el presente estudio, adem&#225;s de las orientaciones verbales, los pacientes recibieron una cartilla y un n&#250;mero de tel&#233;fono celular que podr&#237;a ser utilizado a cualquier hora para resoluci&#243;n de problemas o dudas. Se observ&#243; que tal procedimiento despert&#243; el inter&#233;s y el compromiso de los participantes, facilitando el entendimiento, la adhesi&#243;n y el estrechamiento del v&#237;nculo con el profesional de la salud.</p>
      <p>Algunos trabajos traen la MRPA asociada al telemonitoreo de la PA, que consiste en su medici&#243;n domiciliaria con el monitoreo y manejo remotos a trav&#233;s de la transmisi&#243;n de datos por tel&#233;fono o por internet.</p>
      <p>Los estudios en esta &#225;rea aun son escasos. Sin embargo, algunos resultados preliminares se han mostrado promisorios<sup>19-21</sup>.</p>
      <p>Con base en los resultados obtenidos, se puede vislumbrar la MRPA como una herramienta muy &#250;til tambi&#233;n en el diagn&#243;stico de la verdadera HAR, con reflejos altamente positivos en la adhesi&#243;n del paciente hipertenso a la terap&#233;utica preconizada.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>EL presente estudio no tuvo fuentes de financiamiento externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo es parte de disertaci&#243;n de Maestr&#237;a de Fabiane Rosa R. H. Marui por la UNIFESP.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
